Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice

Figure 1 Changes in body weight and glucose metabolism. A: Folding line graph of body weight change over time for each group of mice (n = 8). The black arrow indicates the point in time when semaglutide and empagliflozin intervened. The ^aP < 0.01 on the first straight line indicates high-fat group (HFD group) vs control group (NCD group); ^bP < 0.01 indicates HFD vs Sema; ^cP < 0.01 indicates HFD vs Empa; B: Comparison of insulin levels in four groups of mice (n = 8). ^aP < 0.01 indicates NCD vs Sema, ^bP < 0.01 indicates HFD vs Sema, ^cP < 0.01 indicates HFD vs Empa, ^dP < 0.01 indicates NCD vs Empa; C: Intraperitoneal glucose tolerance results. ^aP < 0.01 indicates HFD vs NCD, Sema and Empa; D: Comparison of fasting blood glucose levels in the four groups of mice (n = 8). ^aP < 0.01 indicates NCD vs HFD, ^bP < 0.01 indicates NCD vs Sema, ^cP < 0.01 indicates NCD vs Empa. FBG: Fasting blood glucose; HFD: A high-fat group; NCD: A control group.